Abstract:Chemoradiotherapy is the standard treatment for locally advanced squamous cell lung cancer, however, treatment development is urgently needed due to poor prognosis and significant toxicity. Combination therapy of carboplatin and nab-paclitaxel is a useful choice as first-line therapy for patients with advanced non-small cell lung cancer, especially for squamous cell cancer. This prospective phase II study was conducted to explore the efficacy and toxicity of concurrent chemoradiotherapy with nab-paclitaxel, carboplatin and thoracic radiotherapy in unresectable locally advanced squamous cell lung cancer. Patients with unresectable Stage III squamous cell lung cancer were eligible. Patients received nab-paclitaxel weekly at a dose of 60mg/m2, in combination with carboplatin (area under the plasma concentration time curve (AUC) 2) weekly during concurrent chemoradiotherapy. Thoracic radiation was administered at a dose of 66Gy/33 fractions, both three dimensional conformal and intensity modulated radiation therapy were allowed. The consolidation phase chemotherapy consisted of full dose nab-paclitaxel (260 mg/m2 on day 1) and carboplatin (AUC 6 on day 1) every 21 days was administered in two cycles after the concurrent chemoradiotherapy. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), acute radiation esophagitis and pneumonitis.(Clinical trial registration: NCT01494415). Initially, enrollment of 21 patients was planned; however, the trial was prematurely closed due to slow recruitment. Finally, a total of 8 patients were enrolled between January 2012 and July 2015 from one institute. All patients completed concurrent chemoradiotherapy and 6 patients (75.0%) received consolidation chemoradiotherapy. The objective response rate was 62.5%, with partial remission 5 (62.5%), stable disease 2 (25.0%), progressive disease 1 (12.5%), respectively. After a median follow-up of 11.6 (range, 2.0–29.2) months, 5 patients were dead, 3 were alive. The median progression-free survival and overall survival were 12.1 months and 15.2 months, respectively. According to Common Terminology Criteria for Adverse Events (CTCAE) version.4.0, 6 patients (75.0%) experienced acute radiation esophagitis, 4 (50.0%) were grade 2 (G2), 2 (25.0%) were G3; 4 patients (50%) experienced acute radiation pneumonitis, 3 (37.5%) were G2, 1 (12.5%) were G3. No late radiation-induced esophageal and pulmonary toxicity was observed after 1-year follow-up. Concurrent nab-paclitaxel, carboplatin and thoracic radiotherapy is showed to be an effective regimen for patients with unresectable locally advanced squamous cell lung cancer. However, further study should exercise caution due to the severe toxicity of radiation tissue injury especially acute radiation esophagitis.

A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902)

A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A

A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114)

Efficacy and safety of concurrent chemoradiotherapy with carboplatin and nanoparticle albumin-bound paclitaxel.

PUB108 Concurrent Nab-Paclitaxel/Carboplatin Combined with Thoracic Radiotherapy in Locally Advanced Squamous Cell Lung Cancer (NCT01494415)

Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.

A Phase II Study of Concurrent Nab-Paclitaxel/carboplatin Combined with Thoracic Radiotherapy in Locally Advanced Squamous Cell Lung Cancer

Carboplatin plus pemetrexed for the elderly incurable chemo‐naive nonsquamous non–small cell lung cancer: Meta‐analysis

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer

A Study of Weekly Docetaxel and Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer.

Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature

First Line Chemotherapy with Weekly Docetaxel and Cisplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer

Exploring the Efficacy of Pembrolizumab in Combination with Carboplatin and Weekly Paclitaxel for Frail Patients with Advanced Non-Small-Cell Lung Cancer: A Key Investigative Study

Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.

A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)

Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)—IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer

Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study